Ruxolitinib cream for children with vitiligo
Treatments studied
Part of Skin clinical trials.
This study tests whether a cream called ruxolitinib can help children ages 6 to 11 with nonsegmental vitiligo. It aims to see if the cream safely restores color to white patches on the face and body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child is between 6 and 11 years old.
- Has nonsegmental vitiligo (patches on both sides of the body).
- Vitiligo covers at least a small area on the face and some other body parts, but less than 10% of total skin.
- Some of the vitiligo patches on the face have colored (not white) hairs inside them.
- Must stop using any other vitiligo treatments during the study.
- Child has not previously tried a JAK inhibitor treatment for vitiligo that failed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a cream called ruxolitinib for children with nonsegmental vitiligo. It aims to see if the cream can safely help restore skin color in affected areas.
This trial tests an oral medication called zasocitinib to see if it can help repigment skin in adults with nonsegmental vitiligo. It may be an option for people whose vitiligo covers a moderate amount of their body and who have not had certain recent treatments.
This trial tests a cream called ruxolitinib to see if it can safely and effectively restore skin color in children with vitiligo. It may help reduce white patches on the skin.
This trial tests a cream called ruxolitinib for adults with vitiligo on the face and neck that has not responded well to another cream (tacrolimus). The goal is to see if this cream can help bring back skin color.
This study tests how well a cream called ruxolitinib works for vitiligo in real-world conditions. It looks at what factors might make the treatment more or less effective.
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
Hear when a new NonSegmental Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.